MA28478B1 - Derive du benzimidazole et ses utilisations - Google Patents

Derive du benzimidazole et ses utilisations

Info

Publication number
MA28478B1
MA28478B1 MA29333A MA29333A MA28478B1 MA 28478 B1 MA28478 B1 MA 28478B1 MA 29333 A MA29333 A MA 29333A MA 29333 A MA29333 A MA 29333A MA 28478 B1 MA28478 B1 MA 28478B1
Authority
MA
Morocco
Prior art keywords
benzimidazole derivative
benzimidazole
derivative
Prior art date
Application number
MA29333A
Other languages
English (en)
Inventor
Takanobu Kuroita
Hiroki Sakamoto
Mami Ojima
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34858222&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28478(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA28478B1 publication Critical patent/MA28478B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)
MA29333A 2004-02-25 2006-09-22 Derive du benzimidazole et ses utilisations MA28478B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004048928 2004-02-25
US11/031,057 US7157584B2 (en) 2004-02-25 2005-01-07 Benzimidazole derivative and use thereof

Publications (1)

Publication Number Publication Date
MA28478B1 true MA28478B1 (fr) 2007-03-01

Family

ID=34858222

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29333A MA28478B1 (fr) 2004-02-25 2006-09-22 Derive du benzimidazole et ses utilisations

Country Status (33)

Country Link
US (3) US7157584B2 (fr)
EP (3) EP2119715B1 (fr)
JP (2) JP4256852B2 (fr)
KR (1) KR101080029B1 (fr)
CN (2) CN100503605C (fr)
AR (2) AR047972A1 (fr)
AT (2) ATE370136T1 (fr)
AU (1) AU2005214271B8 (fr)
BR (2) BR122012009489B8 (fr)
CA (1) CA2557538C (fr)
CY (5) CY1107008T1 (fr)
DE (3) DE602005002030T2 (fr)
DK (3) DK1857457T3 (fr)
ES (3) ES2293552T3 (fr)
HK (2) HK1098472A1 (fr)
HR (3) HRP20070510T3 (fr)
HU (1) HUS1200008I1 (fr)
IL (1) IL177533A (fr)
LU (1) LU91962I2 (fr)
MA (1) MA28478B1 (fr)
ME (2) ME01643B (fr)
MY (1) MY142807A (fr)
NL (1) NL300802I2 (fr)
NO (2) NO332344B1 (fr)
NZ (1) NZ549755A (fr)
PL (3) PL1857457T3 (fr)
PT (3) PT2119715E (fr)
RS (3) RS52376B (fr)
RU (2) RU2501798C2 (fr)
SI (3) SI1718641T1 (fr)
TW (1) TWI336702B (fr)
WO (1) WO2005080384A2 (fr)
ZA (1) ZA200607241B (fr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
JP4966202B2 (ja) 2004-12-24 2012-07-04 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 治療または予防のための方法
JP4465469B2 (ja) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 循環器病マーカーとしてのインターロイキン１３
KR20070116648A (ko) * 2005-03-30 2007-12-10 다케다 야쿠힌 고교 가부시키가이샤 벤즈이미다졸 유도체 및 안지오텐신 ⅱ 길항제로서의 용도
JP5047156B2 (ja) * 2006-02-27 2012-10-10 武田薬品工業株式会社 医薬パッケージ
WO2007097452A1 (fr) * 2006-02-27 2007-08-30 Takeda Pharmaceutical Company Limited Emballage-coque à usage médical
CA2646379C (fr) 2006-03-20 2014-12-23 The University Of Queensland Methode de traitement prophylactique ou therapeutique
US20090308780A1 (en) * 2006-09-25 2009-12-17 Takeda Pharmaceutical Company Limited Medicinal package
CN101677961B (zh) * 2007-03-28 2012-10-17 武田药品工业株式会社 包含苯并咪唑-7-羧酸酯衍生物和pH控制剂的固体药物组合物
JP2009062296A (ja) * 2007-09-05 2009-03-26 Fujifilm Corp カルボン酸エステル化合物の製造方法
EP2253318B1 (fr) * 2008-03-13 2014-08-06 Daiichi Sankyo Company, Limited Amélioration de la solubilité d'une préparation contenant de l'olmésartan médoxomil
NZ590948A (en) * 2008-07-31 2012-06-29 Takeda Pharmaceutical Solid pharmaceutical composition comprising a diuretic, ph control agent and an oxadiazole
AR073380A1 (es) 2008-09-25 2010-11-03 Takeda Pharmaceutical Composicion farmaceutica solida. comprimido multicapa
MX2011004258A (es) * 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
WO2010075347A2 (fr) 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Méthode de traitement de l'hypertension avec au moins un agent bloquant les récepteurs d'angiotensine ii et de la chlorthalidone
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
MX339570B (es) 2010-05-11 2016-05-31 Janssen Pharmaceutica Nv Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de transportadores de glucosa dependientes de sodio.
WO2012090043A1 (fr) * 2010-12-29 2012-07-05 Jubilant Life Sciences Limited Nouvelles formes à l'état solide d'azilsartan médoxomil et leur procédé de préparation
JP5981940B2 (ja) 2011-01-20 2016-08-31 ジエンス ハンセン ファーマセウティカル カンパニー リミテッド アジルサルタン有機アミン塩、その製造方法及び使用
US9233955B2 (en) 2011-02-08 2016-01-12 Jubilant Life Sciences, Ltd. Process for the preparation of azilsartan medoxomil
CN102138899B (zh) * 2011-03-18 2013-08-21 海南本创医药科技有限公司 阿齐沙坦酯脂质体固体制剂
EA028946B1 (ru) 2011-04-13 2018-01-31 Янссен Фармацевтика Нв Способ получения соединений для применения в качестве ингибиторов sglt2
CN102827153B (zh) * 2011-06-14 2016-10-05 江苏豪森药业集团有限公司 阿齐沙坦的晶型及其制备方法
CN102351853B (zh) * 2011-08-29 2014-03-12 石药集团欧意药业有限公司 一种阿齐沙坦酯化合物、制备方法及其药物组合物
WO2013042066A1 (fr) * 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Procédé de préparation d'azilsartan médoxomil
WO2013042067A1 (fr) 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Procédé de préparation d'un sel de potassium de l'azilsartan médoxomil
WO2013088384A2 (fr) 2011-12-15 2013-06-20 Jubilant Life Sciences Limited Formes à l'état solide d'azilsartan et d'azilsartan médoxomil monopotassique et leur procédé de préparation
US20130158080A1 (en) 2011-12-15 2013-06-20 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating hypertension in black patients
WO2013104342A1 (fr) * 2012-01-14 2013-07-18 Sunshine Lake Pharma Co., Ltd. Formes cristallines de l'azilsartan médoxomil potassique et préparation et utilisations de celles-ci
EP2814826A1 (fr) * 2012-02-02 2014-12-24 Ranbaxy Laboratories Limited Procédé de préparation d'azilsartan médoxomil ou de ses sels pharmaceutiquement acceptables
WO2013124748A1 (fr) * 2012-02-20 2013-08-29 Alembic Pharmaceuticals Limited Nouveaux polymorphes d'azilsartan médoxomil potassique
CZ2012274A3 (cs) * 2012-04-19 2013-10-30 Zentiva, K.S. Zpusob prípravy vysoce cisté draselné soli azilsartanu medoxomilu
WO2013186792A2 (fr) * 2012-06-11 2013-12-19 Msn Laboratories Limited Procédé de préparation de 2-éthoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4- oxadiazol-3-yl)biphényl-4-yl]méthyl}-lh-benzimidazole-7-carboxylate de (5-méthyl-2-oxo-l,3-dioxol-4-yl)méthyle et de ses sels
WO2014009969A2 (fr) * 2012-07-09 2014-01-16 Hetero Research Foundation Nouveaux polymorphes d'azilsartan
WO2014020381A1 (fr) * 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited Forme cristalline inédite d'azilsartan médoxomil potassique
US9314753B2 (en) 2012-08-27 2016-04-19 Stempeutics Research Private Limited Multi plane mixer and separator (MPMS) system
CZ305318B6 (cs) * 2012-09-26 2015-07-29 Zentiva, K.S. Způsob přípravy vysoce čisté draselné soli azilsartanu medoxomilu
WO2014049512A2 (fr) 2012-09-26 2014-04-03 Lupin Limited Nouveau procédé de préparation d'azilsartan médoxomil
CN103709154B (zh) * 2012-09-28 2016-06-15 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
IN2015DN03071A (fr) * 2012-10-09 2015-10-02 Avery Dennison Corp
CN103910720A (zh) * 2013-01-07 2014-07-09 广东东阳光药业有限公司 阿齐沙坦酯的新晶型及其制备方法
CN105153141B (zh) * 2013-02-04 2018-09-25 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
JP6281735B2 (ja) * 2013-03-19 2018-02-21 トーアエイヨー株式会社 急性心不全治療薬の評価方法、及び、急性心不全モデルの作製方法
RU2535005C1 (ru) * 2013-06-11 2014-12-10 Николай Андреевич Козлов Способ лечения грыж межпозвонковых дисков у собак
RU2535004C1 (ru) * 2013-06-11 2014-12-10 Николай Андреевич Козлов Способ лечения грыж межпозвонковых дисков у собак
CN105949182B (zh) * 2013-10-12 2019-03-19 杭州领业医药科技有限公司 阿齐沙坦酯的晶型及其制备方法
WO2015051546A1 (fr) * 2013-10-12 2015-04-16 杭州领业医药科技有限公司 Formes cristallines de l'ester d'azilsartan et leur procédé de préparation
CN104774196B (zh) * 2014-01-09 2017-11-10 武汉朗来科技发展有限公司 一种苯并咪唑衍生物的制备方法
CN104774197B (zh) * 2014-01-09 2017-11-17 武汉朗来科技发展有限公司 一种苯并咪唑衍生物的制备方法
CN105079815A (zh) * 2014-04-30 2015-11-25 广东东阳光药业有限公司 一种阿齐沙坦酯钾组合物及其制备方法
CN104016974A (zh) * 2014-06-24 2014-09-03 浙江天宇药业股份有限公司 阿齐沙坦酯中间体及其合成方法、阿齐沙坦酯的合成方法
CZ2014702A3 (cs) 2014-10-15 2016-04-27 Zentiva, K.S. Způsob přípravy vysoce čistého azilsartanu
CN105622595A (zh) * 2014-11-21 2016-06-01 重庆朗天制药有限公司 一种阿奇沙坦酯钾盐及其中间体新的制备方法
CN105753854A (zh) * 2014-12-16 2016-07-13 重庆朗天制药有限公司 一种阿齐沙坦酯钾盐的新制备方法
US9708306B2 (en) 2015-03-18 2017-07-18 Wuhan Ll Science And Technology Development Co., Ltd Benzimidazole derivatives and preparation process and pharmaceutical uses thereof
CN106032378B (zh) * 2015-03-20 2019-10-25 武汉启瑞药业有限公司 新型arb化合物及其用途
CN104803998B (zh) * 2015-03-26 2017-08-25 晋江市托美汀生物科技有限公司 一种降低杂质含量的方法
US20200179369A1 (en) * 2015-07-29 2020-06-11 Takeda Gmbh Treatment of diabetic nephropathy
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
JP6856365B2 (ja) * 2016-11-30 2021-04-07 株式会社トクヤマ アジルサルタンの製造方法
CN109071519A (zh) * 2016-01-28 2018-12-21 株式会社德山 阿齐沙坦及其制造方法
CN105628824B (zh) * 2016-03-06 2017-10-17 江苏正大清江制药有限公司 一种高效液相色谱法测定阿齐沙坦原料中有关物质的方法
CN107400122B (zh) * 2016-05-20 2020-10-23 武汉朗来科技发展有限公司 化合物及其制备方法、组合物和应用
CN105770876B (zh) * 2016-05-30 2019-09-10 广东天普生化医药股份有限公司 乌司他丁在制备治疗慢性***炎药物中的用途
EP3461822B1 (fr) * 2016-07-11 2022-11-02 Wuhan LL Science And Technology Development Co., Ltd. Forme cristalline de composé chimique, son procédé de préparation, sa composition et son application
RU2623082C1 (ru) * 2016-07-11 2017-06-21 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ коррекции артериальной ригидности у больных ревматоидным артритом
RU2634272C1 (ru) * 2016-08-10 2017-10-24 Закрытое акционерное общество "Санкт-Петербургский институт фармации" Композиция с дезамино-аргинин-вазотоцином для парентерального введения и способ её получения
CN106074416A (zh) * 2016-08-30 2016-11-09 佛山市弘泰药物研发有限公司 一种阿齐沙坦酯钾盐分散片的制备方法
WO2018064945A1 (fr) * 2016-10-08 2018-04-12 武汉朗来科技发展有限公司 Composition pharmaceutique
IN201721047406A (fr) 2017-12-30 2020-06-19 Lupin Limited
CN110237071B (zh) * 2018-03-09 2022-03-22 武汉朗来科技发展有限公司 药物制剂及其应用
CN110237072B (zh) * 2018-03-09 2022-03-25 武汉朗来科技发展有限公司 药物组合物的制备方法
US11081240B2 (en) 2018-06-14 2021-08-03 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin II receptor blocker pharmaceutical composition
WO2019241519A1 (fr) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Méthodes de diminution de la tension artérielle avec une composition pharmaceutique de blocage de canal calcique de type dihydropyridine
WO2020101450A1 (fr) 2018-11-16 2020-05-22 엠에프씨 주식회사 Composés dérivés d'azilsartan, leurs intermédiaires, leur procédé de préparation et composition pharmaceutique les comprenant
WO2020166710A1 (fr) 2019-02-15 2020-08-20 国立大学法人東北大学 Dérivé de 1, 3-dioxolane
KR102220011B1 (ko) 2020-05-15 2021-02-25 대봉엘에스 주식회사 친환경 용매를 이용한 아질사탄의 제조방법 및 이에 관한 핵심 중간체 화합물
CN113912580B (zh) * 2021-11-03 2023-06-02 瑞孚信江苏药业股份有限公司 一种纯化4-(羟甲基)-5-甲基-[1,3]二氧杂环戊烯-2-酮的方法
TW202340183A (zh) 2021-12-28 2023-10-16 日商亞克醫藥股份有限公司 化合物、血管收縮素ii第一型受體拮抗劑及醫藥組合物
KR20240039252A (ko) 2022-09-19 2024-03-26 대봉엘에스 주식회사 안지오텐신 ⅱ 길항제로서의 아질사르탄 디시클로헥실아민 및 이를 유효성분으로 하는 심혈관질환 치료 또는 예방용 약학적 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62290071A (ja) 1986-06-09 1987-12-16 Matsushita Electric Ind Co Ltd 有機電解質二次電池
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
FI112942B3 (fi) 1991-02-21 2012-03-13 Daiichi Sankyo Co Ltd Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksi
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
RU2117668C1 (ru) * 1991-10-23 1998-08-20 Эйсаи Ко., Лтд. Производное оксазолидона или его фармакологически приемлемые соли, фармацевтическая композиция, способ лечения
US5310929A (en) * 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
US5605919A (en) * 1993-02-26 1997-02-25 Takeda Chemical Industries, Ltd. Treatment for viral diseases
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5610314A (en) * 1995-04-03 1997-03-11 Bristol-Myers Squibb Company Process for preparing dioxolenone derivatives used for making prodrug esters and intermediates
US6974806B2 (en) 2000-07-13 2005-12-13 Takeda Pharmaceutical Company Limited Lipid-rich plaque inhibitors
WO2003047573A1 (fr) 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Agents pour améliorer l'état de résistance à l'insuline
PL371319A1 (en) 2002-01-11 2005-06-13 Takeda Pharmaceutical Company Limited Coumarin derivatives, process for their production and use thereof
WO2004048363A1 (fr) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Derives d'imidazole, leur procede de production et d'utilisation
US6972258B2 (en) * 2003-08-04 2005-12-06 Taiwan Semiconductor Manufacturing Co., Ltd. Method for selectively controlling damascene CD bias
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
JP4364171B2 (ja) 2005-07-15 2009-11-11 本田技研工業株式会社 自動車用ドアチェッカ
UA58542U (ru) * 2010-12-16 2011-04-11 Леонид Борисович Борейко Способ фиксирования эвакуационной машины во время вытягивания застрявшей тяжелой машины

Also Published As

Publication number Publication date
PT2119715E (pt) 2012-09-03
SI1718641T1 (sl) 2007-12-31
US7572920B2 (en) 2009-08-11
NO332344B1 (no) 2012-09-03
CY1109610T1 (el) 2014-08-13
PT1718641E (pt) 2007-11-15
EP2119715A1 (fr) 2009-11-18
EP2119715B1 (fr) 2012-05-30
RU2501798C2 (ru) 2013-12-20
ES2293552T3 (es) 2008-03-16
DK1857457T3 (da) 2009-12-21
NO2012017I2 (no) 2012-11-09
CY2012015I2 (el) 2016-12-14
IL177533A (en) 2010-12-30
CY1113084T1 (el) 2016-04-13
NL300802I2 (fr) 2016-05-18
EP1857457B1 (fr) 2009-08-19
JP2009137974A (ja) 2009-06-25
CY2012015I1 (el) 2016-12-14
CN1946717A (zh) 2007-04-11
NO2012017I1 (no) 2012-11-26
DE602005002030D1 (de) 2007-09-27
BRPI0507984B8 (pt) 2023-03-21
CA2557538A1 (fr) 2005-09-01
RS50537B (sr) 2010-05-07
ME01643B (fr) 2010-05-07
DK1718641T3 (da) 2007-12-17
CN100503605C (zh) 2009-06-24
US20050187269A1 (en) 2005-08-25
TWI336702B (en) 2011-02-01
BR122012009489B8 (pt) 2023-03-21
RU2006133898A (ru) 2008-03-27
CY2012016I1 (el) 2016-12-14
RU2009115498A (ru) 2010-10-27
KR101080029B1 (ko) 2011-11-04
ZA200607241B (en) 2008-04-30
US7875637B2 (en) 2011-01-25
EP1857457A2 (fr) 2007-11-21
PL1718641T3 (pl) 2008-01-31
CY1107008T1 (el) 2012-09-26
HK1115118A1 (en) 2008-11-21
CN101381366A (zh) 2009-03-11
EP1718641B1 (fr) 2007-08-15
PL1857457T3 (pl) 2009-12-31
JP2005272451A (ja) 2005-10-06
US20060281795A1 (en) 2006-12-14
DE122012000018I1 (de) 2012-06-06
EP1857457A3 (fr) 2007-12-05
PT1857457E (pt) 2009-09-23
IL177533A0 (en) 2006-12-10
US20090270464A1 (en) 2009-10-29
ATE440095T1 (de) 2009-09-15
BRPI0507984A (pt) 2007-07-24
RS52376B (en) 2012-12-31
WO2005080384A3 (fr) 2006-09-28
DE602005002030T2 (de) 2008-05-08
EP1718641A2 (fr) 2006-11-08
CA2557538C (fr) 2010-08-17
AU2005214271A2 (en) 2005-09-01
HK1098472A1 (en) 2007-07-20
DK2119715T3 (da) 2012-09-10
ME01089B (me) 2013-03-20
TW200530227A (en) 2005-09-16
DE602005016162D1 (de) 2009-10-01
BRPI0507984B1 (pt) 2018-07-03
KR20070020411A (ko) 2007-02-21
AR094588A2 (es) 2015-08-12
NO20064251L (no) 2006-11-22
ES2388945T3 (es) 2012-10-22
NZ549755A (en) 2009-04-30
AU2005214271A1 (en) 2005-09-01
SI2119715T1 (sl) 2012-10-30
CN101381366B (zh) 2011-06-15
RU2369608C2 (ru) 2009-10-10
HRP20090593T1 (hr) 2010-03-31
AR047972A1 (es) 2006-03-15
HRP20120667T2 (hr) 2012-11-30
HRP20070510T3 (en) 2007-12-31
AU2005214271B8 (en) 2011-03-03
AU2005214271B2 (en) 2011-02-24
MY142807A (en) 2011-01-14
ES2331209T3 (es) 2009-12-23
PL2119715T3 (pl) 2012-10-31
JP4256852B2 (ja) 2009-04-22
ATE370136T1 (de) 2007-09-15
WO2005080384A9 (fr) 2006-11-30
WO2005080384A2 (fr) 2005-09-01
LU91962I2 (fr) 2012-05-21
HRP20120667T1 (en) 2012-09-30
SI1857457T1 (sl) 2010-01-29
BR122012009489B1 (pt) 2019-02-19
RS51137B (sr) 2010-10-31
CY2012016I2 (el) 2016-12-14
US7157584B2 (en) 2007-01-02
HUS1200008I1 (hu) 2017-06-28

Similar Documents

Publication Publication Date Title
MA28478B1 (fr) Derive du benzimidazole et ses utilisations
DE602005012825D1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
DE602006021036D1 (de) Substituierte benzimidazole und herstellungsverfahren dafür
MA29039B1 (fr) Dibenzylamines et derives
DE602006021382D1 (de) Lautsprecher und Akustikausgabeverfahren
FI20070841A (fi) Kondensaattorinvaraamismenetelmiä ja -laitteistoja
DE602005002247D1 (de) Lautsprecher
DE602006008061D1 (de) Kommunikationsgerät und Kommunikationsverfahren
DE602006005211D1 (de) HARQ-Verfahren und -System
DE602006011600D1 (de) Audiocodierungseinrichtung und audiocodierungsverfahren
DE602006018050D1 (de) Gerichtete audio-erfassung
DK1863801T3 (da) Benzimidazolderivat og anvendelse deraf
ITMO20050167A1 (it) Apparati e metodi.
DK1870409T3 (da) Benzimidazolforbindelser
DE602006020231D1 (de) Detektionsvorrichtung und -verfahren
DE602005008709D1 (de) Rollsteig
DE602005018446D1 (de) Lautsprechervorrichtung
DE602006021052D1 (de) Kommunikationsvorrichtung und -verfahren
DE602006010018D1 (de) Injektionsvorrichtung sowie Injektionsmethode
DE602005010102D1 (de) Authentifizierungsverfahren und -vorrichtung
DE202005000325U1 (de) Lautsprecher
FI20045252A0 (fi) AV-järjestely sekä ohjain
ITMO20050089A1 (it) Dispositivo e metodo di protezione.
DE102005019875B8 (de) Bohrlehre sowie Bohrvorrichtung
NO20051321D0 (no) Et forbedret teltutbygg